advertisement
Abstract #9886 Published in IGR 5-3
Effect of brimonidine on intraocular pressure in normal tension glaucoma: a short term clinical trial
Gandolfi SA; Cimino L; Mora PEuropean Journal of Ophthalmology 2003; 13: 611-615
PURPOSE: To evaluate the efficacy and safety of 0.2% brimonidine eye drops given twice daily in normal tension glaucoma. PATIENTS AND METHODS: Sixteen consecutive patients fulfilling eligibility criteria (glaucomatous optic neuropathy associated with visual field defect in at least one eye, intraocular pressure (IOP) ≤ 18 mmHg (average of the two highest readings of the round-the-clock curve, including one reading at midnight in supine position), no prior glaucoma therapy, angle wide open, visual acuity 20/40 or better) were enrolled in this prospective, randomized, placebo-controlled clinical trial with crossover design, lasting 30 days for each treatment phase plus 15-day washout in between. Main outcome was IOP (average of the two highest readings of the round-the-clock curve). RESULTS: Mean IOP was significantly reduced by brimonidine (from 17.1 ± 0.7 to 13.9 ± 2.2 mmHg, p < 0.001 (paired Student's t-test)). At the end of the 30-day brimonidine phase, four of 16 subjects showed a ≥30% IOP decrease over baseline. CONCLUSIONS: In the short term, 0.2% brimonidine eye drops can induce a significant IOP decrease in eyes with normal tension glaucoma.
Dr. S.A. Gandolfi, Glaucoma Research and Care Center, University of Parma, Parma, Italy
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
